Do Protagonist Therapeutics' (PTGX) Derisked Drugs Have Blockbuster Potential? [Yahoo! Finance]
J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]
Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.
Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.